{"title":"不溶性给药技术:健康效益和商业潜力综述","authors":"B. Siddalingappa, V. Nekkanti, G. Betageri","doi":"10.13172/2054-4057-1-1-619","DOIUrl":null,"url":null,"abstract":"section 505(b)(2) 2 . The majority of those NDA’s under this section are new formulations. New dosage form, change of forms of drugs (Ester/salt), prodrug/active metabolite of drug and different route of administration are the few changes that the pharmaceutical companies are exploring for 505(b)(2) fillings 3 . The insoluble drugs are being reformulated. Hence this review summarises various solubilisation technologies and their commercial and health benefits. This review discusses drug formulations approved exploring different solubilisation technologies with insight to health benefits and commercial profits.","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"Insoluble drug delivery technologies: review of health benefits and business potentials\",\"authors\":\"B. Siddalingappa, V. Nekkanti, G. Betageri\",\"doi\":\"10.13172/2054-4057-1-1-619\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"section 505(b)(2) 2 . The majority of those NDA’s under this section are new formulations. New dosage form, change of forms of drugs (Ester/salt), prodrug/active metabolite of drug and different route of administration are the few changes that the pharmaceutical companies are exploring for 505(b)(2) fillings 3 . The insoluble drugs are being reformulated. Hence this review summarises various solubilisation technologies and their commercial and health benefits. This review discusses drug formulations approved exploring different solubilisation technologies with insight to health benefits and commercial profits.\",\"PeriodicalId\":11271,\"journal\":{\"name\":\"Drug design and delivery\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug design and delivery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.13172/2054-4057-1-1-619\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug design and delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13172/2054-4057-1-1-619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Insoluble drug delivery technologies: review of health benefits and business potentials
section 505(b)(2) 2 . The majority of those NDA’s under this section are new formulations. New dosage form, change of forms of drugs (Ester/salt), prodrug/active metabolite of drug and different route of administration are the few changes that the pharmaceutical companies are exploring for 505(b)(2) fillings 3 . The insoluble drugs are being reformulated. Hence this review summarises various solubilisation technologies and their commercial and health benefits. This review discusses drug formulations approved exploring different solubilisation technologies with insight to health benefits and commercial profits.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
